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ABSTRACT
Objectives: The role of a defunctioning ileostomy in every anterior rectal resection 
with total mesorectal excision (TME) is still controversial. In this study, we aimed 
to review the current literature to determine the impact of ileostomy creation on 
postoperative outcomes in patients undergoing anterior rectal resection with TME.
Methods: MEDLINE, Embase and Cochrane Library were searched for eligible 
studies. We analyzed data up to October 2017. Eligible studies had to compare 
patients with vs. without a defunctioning ileostomy in rectal cancer surgery and 
comprise data on anastomotic leakage in both groups. The primary outcome was 
anastomotic leakage. Secondary outcomes included the complication rate, mortality, 
reoperation rate, length of hospital stay and 30-day readmission.
Results: Initial search yielded 1,966 articles. Thorough evaluation resulted in 13 
eligible articles which were analyzed. Leakage rate (RR = 0.43, 95% CI 0.28-0.67) and 
the number of reoperations (RR = 0.62, 95% CI 0.40-0.94) were significantly lower 
in the defunctioning stoma group. Morbidity was significantly higher in the stoma 
group (RR = 1.32, 95% CI 1.05–1.65). Analysis of mortality, length of hospital stay 
and readmission rate did not show any significant differences.
Conclusion: A defunctioning ileostomy may decrease the anastomotic leakage 
rate, additionally significantly reducing the risk of reoperations but it may also 
increase the overall complication rate. The presence of the protective stoma has no 
effect on mortality, length of hospital stay and readmission rate.
INTRODUCTION
The standard potentially curative treatment option 
for rectal cancer is surgery, which is often combined with 
preoperative radio or chemoradiotherapy [1]. In 1982 
Heald introduced the total mesorectal excision (TME) that 
has become the standard technique to dissect in anatomical 
planes with the aim to obtain a complete removal of 
mesorectum with intact mesorectal fascia [2]. Despite 
improvements in surgical technique and development 
of modern equipment, including laparoscopic surgery, 
TME with primary anastomosis is still associated with a 
significant risk of symptomatic anastomotic leakage (AL), 
ranging between 3% and 24% [3–5]. The rate depends 
mainly on the tumor size and location, neoadjuvant 
irradiation and patient’s general status (male gender, 
malnutrition, steroid use, obesity and advanced age are all 
associated with increased risk) [6–8]. Patients with low 
rectal cancer are prone to higher rate of intraoperative 
adverse events and permanent colostomy which results 
in worse functional outcome compared with high rectal 
cancer [9, 10]. The prevention of an anastomotic leakage 
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in TME by proximal fecal diversion with loop ileostomy 
has been a subject of debate for many years. It has been 
suggested that defunctioning ileostomy ameliorates 
the septic effects of a leak, which potentially leads to 
pelvic abscess formation and peritonitis [11, 12]. Several 
randomized trials and comparative studies proposed the 
creation of protective ileostomy as a means to reduce 
the risk of AL. However, authors are not unanimous on 
whether the protective stoma is required in all cases of 
TME. Unfortunately, despite many risk factors being 
identified, it is not possible to predict which patients 
will develop anastomotic leakage [13]. The fundamental 
question is which patients will benefit from diversion. In 
fact, in real clinical scenario most patients undergoing 
TME do not develop leakage at all. For this reason, the 
question arises whether strategy of elective defunctioning 
ileostomy in all patients is not an overtreatment in 
majority of them. In addition, the presence of stoma 
may also increase the risk of complications related to 
stoma itself, but also to the subsequent stoma closure 
[14–16]. On the other hand, anastomotic leakage is not 
only associated with a prolonged length of hospital stay 
or increased morbidity, but may also delay postoperative 
chemotherapy compromising long-term survival [17, 18]. 
In a review by Hanna et al. authors concluded that creation 
of defunctioning ileostomy (being the fecal diversion 
procedure of choice) should be a joint one between the 
patient and surgeon [19]. However, results of most 
recently published studies may provide fresh perspective.
Therefore, our aim was to review the current 
literature to assess the benefits of defunctioning ileostomy 
creation in patients undergoing anterior rectal resection 
with TME.
RESULTS
The initial reference search yielded 1,966 articles. 
After removing 406 duplicates, 1,560 articles were 
evaluated through titles and abstracts. This produced 
147 papers suitable for full-text review and ultimately, 
we enrolled 13 studies [20–32]. Out of those, 4 were 
randomized controlled trials (RCTs) and 9 were 
comparative studies with a total of 2,366 patients (1,026 
with and 1,340 without protective ileostomy). Table 1 
presents characteristics of included studies. A PRISMA 
flowchart of the analyzed studies is presented in Figure 1. 
The funnel plot of publication bias is presented in Figure 
2. The funnel plot is asymmetric due to the increased 
heterogeneity of included articles. Missing studies in the 
middle and right of the plot may result from publication 
bias. However, due to the small number of included 
articles test power could be too low to distinguish 
chance from real asymmetry. Quality assessment of 
studies is presented in Table 1. Additional, more detailed 
information is included in Supplementary Table 1.
Anastomotic leakage was reported in all 13 studies. 
The analysis (Figure 3) showed significant differences 
among the studied groups, 62/1,026 (6.04%) in the group 
with a defunctioning stoma vs. 132/1,340 (9.85%) in the 
group without it: RR=0.43, 95% CI 0.28 - 0.67, p for effect 
= 0.0002, p for heterogeneity = 0.10, I2= 35%. However, 
when 95% prediction interval was calculated it was not 
statistically significant [0.14 ; 1.28].
Data on the complication rate were present in 8 
included articles. The analysis established significant 
differences in the complication rate between the group 
with a defunctioning stoma 234/534 (43.82%) vs. 161/486 
(33.13%) in the group without it: RR = 1.32, 95% CI 1.05–
1.65, p for effect = 0.02, p for heterogeneity = 0.12, I2 = 
38% (Figure 4). In this outcome, 95% prediction interval 
was not significant [0.77; 2.25].
Mortality was presented in 11 out of 13 included 
studies. In 4 papers, 30-day mortality was reported. Chude 
et al. did not specify for what period of time the mortality 
was calculated. As many as 6 authors reported no deaths in 
the analyzed groups. There were no statistically significant 
differences among the studied groups 2/966 (0.21%) vs. 
6/1,260 (0.48%): RR = 0.43, 95% CI 0.12 – 1.60 p for 
effect = 0.21, p for heterogeneity =0.84, I2 =0% (Figure 5).
Data on reoperations were present in 8 included 
articles. The analysis established significant differences 
in the number of reoperations between patients with vs. 
without the stoma 48/630 (7.62%) vs. 76/581 (13.08%): 
RR = 0.62, 95% CI 0.40-0.94, p for effect =0.02, p for 
heterogeneity = 0.31, I2 =15% (Figure 6). 95% prediction 
interval for this outcome was 0.18 to 0.97.
The mean length of hospital stay (LOS) was 
reported in 12 papers. All of them included the primary 
LOS (excluding potential readmissions). The mean LOS 
for the group with a defunctioning stoma was 10.1±5.05 
days, while for the group without it 10.66±5.96 days. 
There were no statistically significant variations among 
the studied groups: mean difference = -0.56, 95% CI -2.70 
-1.59, p for effect = 0.61, p for heterogeneity <0.00001, I2 
= 91% (Figure 7).
Readmissions were presented in 4 out of 13 included 
studies. There were no statistically significant variations 
among the studied groups 41/288 (14.24%) vs. 35/280 
(12.5%): RR = 1.12, 95% CI 0.71 – 1.77, p for effect = 
0.62, p for heterogeneity = 0.37, I2 = 5% (Figure 8).
DISCUSSION
This systematic review, with a meta-analysis, 
is based on 13 studies (4 RCTs and 9 comparative 
studies) with more than 2,000 patients. It showed that a 
defunctioning ileostomy is associated with a decrease in 
the anastomotic leakage rate and reoperations, an increase 
of the overall complication rate with no influence on 
mortality, length of hospital stay and readmission rate.
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Nowadays, the role of ileostomy in every anterior 
rectal resection with TME is still controversial. There are 
no established guidelines that would impose its creation. 
Numerous studies are available in the literature, both 
showing its benefits and its adverse effects. On the one 
hand, the creation of a protective stoma during primary 
surgery is intended to lower the rate of clinical anastomotic 
leakage, which is one of the most severe complications 
occurring after anterior rectal resection with TME [33, 
34]. It can be found in about 10% of patients operated 
on due to oncological causes and may lead to increased 
mortality, delays in the introduction of adjuvant therapy, 
thus disrupt patient treatment leading to worse results 
[35–37]. On the other hand, a defunctioning ileostomy 
is associated with more complications (high stoma flow, 
prolapse, kidney failure, skin excoriation etc.) and some 
authors report that it also prolongs hospital stay [38, 39]. 
Additionally, these patients require another surgery, which 
also involves the risk of complications, and not all patients 
undergo surgical closure of the stoma [8, 40]. The risk of 
a defunctioning ileostomy is repeatedly reported by many 
authors to be in a range from 8% to 25% [41]. Despite 
the suggestion that ileostomy should be closed within 
10–12 weeks, this is not commonly practiced, and the 
median time to reversal is 30 weeks [42]. Postoperative 
chemotherapy also prolonged the period of time to reversal 
and in this group of patients the period of time to stoma 
closure is up to 40 weeks [43]. Creating a stoma is also 
associated with higher costs of hospitalization. Floodeen 
et al. showed that a defunctioning stoma in low anterior 
resection was associated with higher costs for 5 years after 
surgery, despite the cost-savings associated with a reduced 
frequency of anastomotic leakage [44]. These results 
seem to be significant, especially since more than 90% 
of patients do not benefit from the stoma [45]. Another 
solution could be creating a ghost ileostomy. In this group 
of patients it is possible to create a loop ileostomy only 
in case of anastomotic leakage and without the need for 
laparotomy. However, even pioneers of this technique 
recommend it only in patients with low and medium 
risk of this complication [46, 47]. We have observed that 
creating a protective stoma may be beneficial in reducing 
both the rate of anastomotic leakage and reoperations. 
In order to evaluate significant results of random-
effects data pooling we have used prediction intervals to 
fully estimate their clinical application. The prediction 
interval for anastomotic leakage was 0.14-1.28, thus the 
clinical application may be restricted in some settings. 
Table 1: Baseline characteristics
Study Year
Type 
of 
study
No. of 
patients 
in study/ 
control 
group
JADAD/
NOS 
quality 
score
Neoadjuvant 
therapy 
in study/ 
control 
group (%)
Type of 
operation 
laparoscopic/
open
Permanent/ 
End stomy
Type of 
resection
Definition 
of 
anastomotic 
leakage
Anderin [20] 2015 CS 139/148 7 94.9/76.4 OP ND TME clinical
Chude [21] 2008 RCT 136/120 0 ND ND ND LAR clinical
Gong [22] 2013 CS 26/36 6 ND OP 0/26 TME ND
Gumbau [23] 2015 CS 58/46 5 77.6/36.9 LAP/OP ND TME clinical
Ihnat [24] 2016 CS 78/73 8 35.9/30.1 LAP 4/78 TME radiological /clinical
Karahasanoglu 
[25] 2011 CS 23/54 6 21.7/1.8 LAP 3/23
TME/
PME ND
Kim [26] 2015 CS 67/35 6 0/0 LAP/OP 4/67 LAR clinical
Maroney [27] 2016 CS 57/42 8 75.4/23.8 LAP/OP 5/57 LAR clinical
Mrak [28] 2016 RCT 94/72 3 61.7/38.9 OP 2/94 TME clinical
Seo [29] 2013 CS 246/590 7 63.8/24.1 OP 9/246 TME clinical
Skrovina [30] 2011 CS 50/64 7 ND LAP 1/50 TME clinical
Thoker [31] 2014 RCT 34/44 3 ND OP 3/34 LAR radiological
Urlich [32] 2009 RCT 18/16 3 83.3/50 OP ND TME radiological /clinical
ND - no data, OP - open approach, LAP - laparoscopic approach, RCT - randomized controlled trial, CS - comparative 
study, TME – total mesorectal excision, PME – partial mesorectal excision, LAR – low anterior resection.
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However, it has been shown clinically relevant in terms 
of reoperations. Leakage after rectal resection with TME 
is one of the most serious complications. It is due to the 
fact, that the large proportion of these patients require 
reoperation. In addition it is associated with relatively high 
mortality risk [48, 49]. Many patients with leakage in the 
group without a stoma require conversion to colostomy 
(Hartmann procedure) that in some cases is permanent. 
The percentage of patients with a permanent stoma in 
the included studies is presented in Table 1 and ranges 
between 0% and 13% [22, 25]. What is worth mentioning 
is that ileostomy allows in many patients an effective 
treatment of leaks, including endoVAC therapy which is 
highly successful in this indication [50–52].
One of the well-known risk factors for leaks is 
neoadjuvant treatment [53, 54]. In the analyzed studies, 
patients with neoadjuvant treatment were more often 
treated with anastomosis accompanied by a protective 
stoma than not (67.7% vs. 32.8%), which may create a 
bias. Even though the higher proportion of patients with 
a stoma had neoadjuvant treatment, the proportion of 
leaks in this group was smaller than in the group without 
a protective stoma. This speaks for benefits of fecal 
diversion.
Figure 2: Funnel plot.
Figure 1: PRISMA flowchart.
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The overall complication rate was higher in the 
group of patients with a defunctioning ileostomy compared 
to patients without it. The prediction interval for morbidity 
ranged from 0.77 to 2.25 meaning that not in every clinical 
situation patients with stoma may be at greater risk of 
developing complications. Despite the decreased leakage 
rate in the protective stoma group, there is a whole range 
of stoma-related complications mentioned previously. On 
the one hand, a protective stoma reduces the incidence of 
leakage (one of the most severe complications). On the 
other hand, it leads to a higher incidence of complications 
(mainly less severe) [55–57]. It seems, however, that 
the patient with a stoma still benefits. Presence of stoma 
reduces one of the heaviest complications – leakage which 
mostly requires reoperation. The higher morbidity rate 
results mainly from an increased number of less severe 
Figure 3: Pooled estimates of anastomotic leakage after rectal resection with versus without defunctioning ileostomy.
Figure 4: Pooled estimates of complication rate after rectal resection with versus without defunctioning ileostomy.
Figure 5: Pooled estimates of mortality after rectal resection with versus without defunctioning ileostomy.
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complications, requiring mostly only pharmacological 
treatment and a slightly longer hospital stay. Mostly, 
they do not affect the delay of adjuvant treatment. We 
have not been able to provide a more detailed division 
of complications with a separate analysis due to lack of 
detailed data.
In our meta-analysis there were no significant 
differences in the mortality rate between the groups. The 
mortality rate after anterior rectal resection with TME 
reported in the literature ranges between 1% to 8% and 
rises to 6-22% when anastomotic leakage occurs [8, 58]. 
In our analysis it was much lower – nearly 0.2% in the 
stoma group and 0.5% in the group without it. Another 
interesting consideration is whether stoma creation affects 
long-term outcomes, including the 5-year survival. This 
assessment is, however, very difficult, mainly due to a 
Figure 6: Pooled estimates of reoperations after rectal resection with versus without defunctioning ileostomy.
Figure 7: Pooled estimates of length of hospital stay comparing rectal resection with versus without defunctioning 
ileostomy.
Figure 8: Pooled estimates of readmission rate after rectal resection with versus without defunctioning ileostomy.
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large number of disturbing factors. The length of hospital 
stay and readmission rate did not differ significantly 
between the analyzed groups.
One of the limitations of this study is the variability 
of the quality of the included studies. We included both 
randomized and non-randomized studies. Besides, we 
were not able to fully evaluate types of rectal resections 
performed. In 8 studies the authors reported them as 
TME, whereas in 4 it was low anterior resection (LAR) 
and in one study both TME and partial total mesorectal 
excision (PME) in cases of cancer of the upper rectum. 
However, taking into consideration the relatively recent 
date of publication we may assume that all cases of LAR 
were performed according to TME standards at the same 
time. The majority of trials were clinical control studies, 
only 4 were RCTs. Comparative studies have a potential 
risk of selection bias – a surgeon could decide to create a 
defunctioning stoma in the case of patients with a higher 
risk for AL. Another cause of bias may be the difference 
in the height of the anastomosis, that is the length between 
the anal verge and anastomosis. It is not reported by all 
authors. It seems, however, that lower anastomosis is 
associated with a greater risk of anastomotic leakage [9, 
11]. The included studies differed in the percentage of 
neoadjuvant treatment as mentioned above. In addition, 
the large heterogeneity of the included studies restrains us 
from drawing strong conclusions in some results. Despite 
numerous studies on the subject, it appears that further 
well-designed randomized studies separately with or 
without neoadjuvant treatment are needed to better define 
the group of patients that would need a defunctioning 
ileostomy and perhaps establishing a standard for its 
selective use. Additionally the results should be considered 
with caution since evaluation of funnel plot revealed 
publication bias.
This meta-analysis shows on the large population 
that a defunctioning ileostomy may decrease the 
anastomotic leakage rate, additionally significantly 
reducing the risk of reoperation but it may also increase 
the overall complication rate. Creating or no protective 
stoma has no effect on mortality, the length of hospital 
stay and readmission rate.
MATERIALS AND METHODS
Study selection
A search was conducted by two researchers (NG, 
MW) in October 2017, using the Medline (through Ovid 
and PubMed), Embase and Cochrane databases to identify 
all eligible studies with language restricted to English. 
The search terms used were “ileostomy”, “stomy”, 
“cancer”, “adenocarcinoma”, “tumor”, “malignancy”, 
“neoplasm”, “defunctioning”, “diverting”, “protective”, 
“loop”, “rectal” and their abbreviations with the addition 
of Boolean operators “AND” and “OR”. References of 
all retrieved articles were checked for potentially eligible 
articles.
Data extraction
Four researchers (NG, MW, MM, JW) identified 
and selected citations from the search independently. 
Each citation was assessed by at least two researchers. 
In the event of uncertainties relating to inclusion, a 
third reviewer was consulted (MP) until consensus was 
reached. Extraction of data from every selected article was 
conducted by at least two researchers. Basic information 
regarding the included studies were first author, year of 
publication, study design, number of patients in each 
group and type of operation (laparoscopic/open).
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) studies 
comparing patients with vs. without a defunctioning 
ileostomy in rectal resection (2) data on anastomotic 
leakage in both groups, (3) paper in English.
Studies were excluded when: (1) full extraction was 
not possible (2) review or meta-analysis (3) decompression 
techniques other than ileostomy, (4) single group studies.
In the case of studies comprising the same patient 
cohort, only the most recent or complete study was 
included (Table 1).
Outcomes of interest
The primary outcome of interest was the anastomotic 
leakage rate. Secondary outcomes involved short-term 
outcomes: complication rate, mortality, reoperation rate, 
length of hospital stay and 30-day readmission.
Statistical analysis
Analysis was performed using RevMan 5.3 
(freeware from the Cochrane Collaboration). Statistical 
heterogeneity and inconsistency were measured using 
Cochran’s Q tests and I2, respectively. Qualitative 
outcomes from individual studies were analyzed to assess 
individual and pooled risk ratios (RR) with pertinent 
95% confidence intervals (CI) favoring surgery with a 
protective ileostomy over surgery without it. When the 
study included medians and interquartile ranges, we 
calculated the mean ± SD using a method proposed by 
Hozo et al. [59]. Weighted mean differences (WMD) with 
95% CI were presented for quantitative variables using 
the inverse variance random-effects method. Statistical 
significance was observed with two-tailed 0.05 level for 
hypothesis and with 0.10 for heterogeneity testing, while 
unadjusted p-values were reported accordingly. Clinical 
application of significant results acquired with random-
effects data pooling was evaluated using prediction 
intervals according to Riley et al. [60].
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Non-randomized studies were evaluated with the 
Newcastle–Ottawa Scale (NOS), which consists of three 
factors: patient selection, comparability of the study 
groups and assessment of outcomes. A score of 0 to 9 was 
assigned to each study and studies achieving a score of 
6 or greater were considered high quality. Randomized 
studies were assessed with the Jadad scale. This study was 
performed according to the Preferred Reporting Items for 
Systematic reviews (PRISMA) guidelines and MOOSE 
consensus statement [61, 62].
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